Met (MET proto-oncogene, receptor tyrosine kinase) - Rat Genome Database

Send us a Message

Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Gene: Met (MET proto-oncogene, receptor tyrosine kinase) Rattus norvegicus
Symbol: Met
Name: MET proto-oncogene, receptor tyrosine kinase
RGD ID: 3082
Description: Enables several functions, including beta-catenin binding activity; hepatocyte growth factor receptor activity; and phospholipase binding activity. Involved in several processes, including neurogenesis; positive regulation of cellular component organization; and positive regulation of macromolecule metabolic process. Located in several cellular components, including excitatory synapse; postsynaptic membrane; and sperm flagellum. Biomarker of several diseases, including acute kidney failure; hepatobiliary system cancer (multiple); liver benign neoplasm; pancreatitis; and periodontitis. Human ortholog(s) of this gene implicated in autistic disorder; autosomal recessive nonsyndromic deafness 97; carcinoma (multiple); distal arthrogryposis; and multiple myeloma. Orthologous to human MET (MET proto-oncogene, receptor tyrosine kinase); PARTICIPATES IN scatter factor/hepatocyte growth factor signaling pathway; altered scatter factor/hepatocyte growth factor signaling pathway; E-cadherin signaling pathway; INTERACTS WITH 1,2-dimethylhydrazine; 17beta-estradiol; 2,3,7,8-tetrachlorodibenzodioxine.
Type: protein-coding
Previously known as: c-Met; hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; Hgfr; met proto-oncogene; met proto-oncogene tyrosine kinase; proto-oncogene c-Met; scatter factor receptor; SF receptor; tyrosine-protein kinase Met
RGD Orthologs
Green Monkey
Naked Mole-Rat
Alliance Genes
More Info more info ...
Allele / Splice: Metem1Sage  
Genetic Models: SD-Metem1Sage
Is Marker For: Strains:   BB/OK  
Candidate Gene For: Hcar2
Latest Assembly: mRatBN7.2 - mRatBN7.2 Assembly
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2445,790,456 - 45,898,139 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl445,790,791 - 45,897,876 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx450,810,987 - 50,887,772 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0446,731,994 - 46,808,783 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0445,147,966 - 45,224,887 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0444,747,467 - 44,854,628 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl444,774,741 - 44,852,665 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0445,354,290 - 45,461,638 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4443,134,183 - 43,211,355 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1443,280,529 - 43,358,391 (+)NCBI
Celera441,091,921 - 41,169,063 (+)NCBICelera
Cytogenetic Map4q22NCBI
JBrowse: View Region in Genome Browser (JBrowse)

Disease Annotations     Click to see Annotation Detail View
acute kidney failure  (IEP)
Acute Liver Failure  (IEP)
acute myeloid leukemia  (ISO)
adenocarcinoma  (ISO)
Animal Disease Models  (ISO)
Animal Hepatitis  (IEP)
arteriosclerosis  (ISO)
autism spectrum disorder  (ISO,ISS)
autistic disorder  (ISO)
autosomal recessive nonsyndromic deafness 97  (ISO)
Bile Duct Neoplasms  (ISO)
breast cancer  (ISS)
breast carcinoma  (ISO)
Carcinogenesis  (ISO)
carcinoma  (ISO)
Cardiomegaly  (IEP)
childhood hepatocellular carcinoma  (ISO)
cholangiocarcinoma  (IEP,ISO)
Chronic Hepatitis  (ISO)
cognitive disorder  (ISO)
colorectal cancer  (ISO)
Colorectal Neoplasms  (ISO)
congenital diaphragmatic hernia  (ISO)
congenital disorder of glycosylation Ii  (ISO)
Copper-Overload Cirrhosis  (ISO)
Cystic, Mucinous, and Serous Neoplasms  (ISO)
disease of cellular proliferation  (ISO)
distal arthrogryposis type 1  (ISO)
Distal Arthrogryposis Type 11  (ISO)
distal arthrogryposis type 1A  (ISO)
Endometrial Neoplasms  (IAGP)
Esophageal Neoplasms  (ISO)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (IEP)
Experimental Liver Neoplasms  (ISO)
fatty liver disease  (ISO)
Gallbladder Neoplasms  (ISO)
gastrinoma  (ISO)
genetic disease  (ISO)
gestational diabetes  (ISS)
Gilles de la Tourette syndrome  (ISS)
glioblastoma  (ISO)
hepatoblastoma  (ISO)
hepatocellular carcinoma  (IEP,ISO)
Hepatomegaly  (ISO)
Hereditary Neoplastic Syndromes  (ISO)
high grade glioma  (IEP)
Hodgkin's lymphoma  (ISO)
Hypertriglyceridemia  (ISO)
intellectual disability  (ISO)
invasive ductal carcinoma  (ISO)
Kidney Neoplasms  (ISO)
large cell carcinoma  (ISO)
liver benign neoplasm  (IEP)
lung carcinoma  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
lung squamous cell carcinoma  (ISO)
Lymphatic Metastasis  (ISO)
lymphedema  (ISO)
malignant astrocytoma  (ISO)
malignant mesothelioma  (ISO)
melanoma  (ISO)
multiple myeloma  (ISO)
Nasal Polyps  (ISO)
Neoplasm Invasiveness  (ISO)
Neoplasm Metastasis  (ISO)
Nerve Sheath Neoplasms  (ISO)
neuroblastoma  (ISO)
non-alcoholic fatty liver disease  (ISO)
nonsyndromic deafness  (ISO)
oral squamous cell carcinoma  (ISO)
Osteofibrous Dysplasia  (ISO)
osteosarcoma  (ISO)
ovarian cancer  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic cancer  (IEP,ISO)
pancreatic ductal carcinoma  (ISO)
pancreatitis  (IEP)
papillary renal cell carcinoma  (ISO)
periodontitis  (IEP)
pleomorphic xanthoastrocytoma  (ISO)
primary biliary cholangitis  (ISO)
prostate carcinoma  (ISO)
Prostatic Neoplasms  (ISO)
renal carcinoma  (ISO)
renal cell carcinoma  (ISO)
Renal Cell Carcinoma 1  (ISO)
Reperfusion Injury  (IEP)
sarcoma  (ISO)
schizophrenia  (ISO)
sinusitis  (ISO)
Spinal Cord Injuries  (IEP)
squamous cell carcinoma  (ISO)
Stomach Neoplasms  (ISO)
tongue squamous cell carcinoma  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(-)-epigallocatechin 3-gallate  (ISO)
(1->4)-beta-D-glucan  (ISO)
1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane  (ISO)
1,1-dichloroethene  (ISO)
1,2-dimethylhydrazine  (EXP,ISO)
1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester  (ISO)
17beta-estradiol  (EXP,ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,3',4,4',5,5'-Heptachlorobiphenyl  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2-amino-2-deoxy-D-galactopyranose  (EXP,ISO)
2-hydroxypropanoic acid  (ISO)
3,3',4,4',5-pentachlorobiphenyl  (EXP,ISO)
3-Nitrobenzanthrone  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-aminosalicylic acid  (ISO)
4-phenylbutyric acid  (EXP)
5-aza-2'-deoxycytidine  (ISO)
6-propyl-2-thiouracil  (EXP)
6alpha-methylprednisolone  (ISO)
9-cis-retinoic acid  (ISO)
ABT-737  (ISO)
acetamide  (EXP)
acetic acid  (EXP)
acetylsalicylic acid  (ISO)
acrylamide  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
all-trans-retinoic acid  (ISO)
ammonium chloride  (EXP)
amodiaquine  (ISO)
apigenin  (ISO)
aristolochic acid A  (ISO)
arsenite(3-)  (ISO)
arsenous acid  (ISO)
atrazine  (EXP)
azathioprine  (ISO)
benzatropine  (ISO)
benzo[a]pyrene  (ISO)
benzo[a]pyrene diol epoxide I  (ISO)
bicalutamide  (ISO)
bilirubin IXalpha  (ISO)
biperiden  (ISO)
bis(2-ethylhexyl) phthalate  (ISO)
bisphenol A  (EXP,ISO)
bisphenol F  (ISO)
bromfenac  (ISO)
Butylparaben  (EXP)
C60 fullerene  (EXP)
cabozantinib  (ISO)
cadmium atom  (ISO)
cadmium dichloride  (ISO)
caffeine  (ISO)
cefaloridine  (EXP)
celecoxib  (EXP)
CGP 52608  (ISO)
choline  (ISO)
cisplatin  (ISO)
clavulanic acid  (ISO)
clofarabine  (ISO)
cobalt atom  (ISO)
cobalt dichloride  (ISO)
cocaine  (ISO)
copper atom  (ISO)
copper(0)  (ISO)
coumarin  (ISO)
crizotinib  (ISO)
crocidolite asbestos  (EXP,ISO)
cyclosporin A  (ISO)
cyproconazole  (ISO)
deoxynivalenol  (ISO)
diarsenic trioxide  (ISO)
diazinon  (EXP)
Dibromoacetonitrile  (EXP)
diclofenac  (ISO)
Dictamnine  (ISO)
diethylstilbestrol  (ISO)
dioxygen  (ISO)
dorsomorphin  (ISO)
doxorubicin  (ISO)
entacapone  (ISO)
enzacamene  (EXP)
erlotinib hydrochloride  (ISO)
esmolol  (ISO)
ethambutol  (ISO)
ethanol  (EXP,ISO)
etodolac  (ISO)
Fexofenadine hydrochloride  (ISO)
fludrocortisone  (ISO)
flutamide  (ISO)
folic acid  (ISO)
furan  (EXP)
gallic acid  (ISO)
geldanamycin  (ISO)
genistein  (ISO)
ginsenoside Rg1  (ISO)
glutathione  (ISO)
graphite  (EXP)
heparin  (ISO)
hexadecanoic acid  (ISO)
Iproniazid  (ISO)
ivermectin  (ISO)
kaempferol  (ISO)
ketoconazole  (ISO)
L-ascorbic acid  (ISO)
L-methionine  (ISO)
lead diacetate  (EXP)
lead nitrate  (ISO)
lead(0)  (EXP)
leflunomide  (EXP)
licocoumarone  (ISO)
lipopolysaccharide  (EXP,ISO)
lumiracoxib  (ISO)
malathion  (ISO)
malonaldehyde  (ISO)
mebendazole  (ISO)
menadione  (ISO)
methotrexate  (ISO)
methyltestosterone  (ISO)
microcystin-LR  (ISO)
mifepristone  (ISO)
minoxidil  (ISO)
myricetin  (ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
nefazodone  (ISO)
nevirapine  (ISO)
niclosamide  (EXP)
nimesulide  (ISO)
nomifensine  (ISO)
ochratoxin A  (ISO)
oleanolic acid  (ISO)
orlistat  (ISO)
osimertinib  (ISO)
oxybutynin  (ISO)
paracetamol  (ISO)
paraquat  (EXP)
parecoxib  (ISO)
PCB138  (ISO)
PD173074  (ISO)
penbutolol  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
PHA-665752  (ISO)
phenobarbital  (ISO)
Phenoxybenzamine  (ISO)
phentolamine  (ISO)
phenylmercury acetate  (ISO)
pioglitazone  (ISO)
piperine  (ISO)
pirinixic acid  (ISO)
piroxicam  (ISO)
pirprofen  (ISO)
poly(propylene imine) macromolecule  (ISO)
potassium dichromate  (ISO)
prednisolone  (ISO)
procyclidine  (ISO)
propofol  (ISO)
protriptyline  (ISO)
quercetin  (ISO)
rac-lactic acid  (ISO)
resveratrol  (ISO)
retinyl acetate  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
SB 431542  (ISO)
sevoflurane  (ISO)
sodium arsenite  (EXP,ISO)
sodium aurothiomalate  (ISO)
sodium cholate  (ISO)
sulindac sulfide  (ISO)
sunitinib  (ISO)
tanespimycin  (EXP,ISO)
temozolomide  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (EXP,ISO)
tetrachloromethane  (EXP,ISO)
thioacetamide  (EXP)
thymoquinone  (ISO)
tienilic acid  (ISO)
titanium dioxide  (ISO)
tolcapone  (ISO)
trazodone  (ISO)
triazines  (ISO)
trichloroethene  (EXP,ISO)
trichostatin A  (ISO)
triclosan  (ISO)
Trihexyphenidyl  (ISO)
trimellitic anhydride  (ISO)
triptonide  (ISO)
troglitazone  (ISO)
Tungsten carbide  (ISO)
ursodeoxycholic acid  (EXP)
valproic acid  (ISO)
vemurafenib  (ISO)
vinclozolin  (EXP)
zafirlukast  (ISO)
zearalenone  (ISO)
zinc sulfate  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
adult behavior  (ISO)
brain development  (ISO)
branching morphogenesis of an epithelial tube  (IEA,ISO)
cardiac muscle cell development  (ISO)
cardiac muscle contraction  (ISO)
cell migration  (IBA)
cellular response to arsenic-containing substance  (IEP)
cellular response to glucose stimulus  (IEP)
cellular response to growth factor stimulus  (IEP)
cellular response to inorganic substance  (IEP)
cellular response to interleukin-6  (IEP)
cellular response to peptide hormone stimulus  (IEP)
central nervous system neuron differentiation  (IEP)
chemical synaptic transmission  (ISO)
endothelial cell morphogenesis  (IEA,ISO)
establishment of localization in cell  (ISO)
establishment of skin barrier  (IEA,ISO)
excitatory postsynaptic potential  (ISO)
flagellated sperm motility  (IMP)
glucose homeostasis  (ISO)
glucose transmembrane transport  (ISO)
hepatocyte growth factor receptor signaling pathway  (ISO)
lactation  (IEP)
liver development  (IBA,IEP,ISO)
male gonad development  (IEP)
modulation of chemical synaptic transmission  (ISO)
muscle cell migration  (ISO)
muscle organ development  (ISO)
myoblast proliferation  (ISO)
myotube differentiation  (ISO)
negative regulation of gene expression  (ISO)
negative regulation of hydrogen peroxide-mediated programmed cell death  (IEA,ISO)
negative regulation of peptidyl-threonine phosphorylation  (IMP)
negative regulation of Rho protein signal transduction  (IEA,ISO)
negative regulation of stress fiber assembly  (IEA,ISO)
negative regulation of thrombin-activated receptor signaling pathway  (IEA,ISO)
negative regulation of transcription by RNA polymerase II  (IMP)
negative regulation of transforming growth factor beta production  (ISO)
nervous system development  (IBA)
neuron differentiation  (IBA)
neuron migration  (IDA,IMP)
oligodendrocyte development  (IEP)
pancreas development  (IBA,IEP)
phagocytosis  (IBA)
phosphorylation  (IEA)
placenta development  (ISO)
positive chemotaxis  (IEA,ISO,ISS)
positive regulation of dendrite morphogenesis  (IMP)
positive regulation of DNA replication  (IMP)
positive regulation of endothelial cell chemotaxis  (IEA,ISO,ISS)
positive regulation of gene expression  (IMP)
positive regulation of glucose transmembrane transport  (ISO)
positive regulation of MAPK cascade  (ISO)
positive regulation of microtubule polymerization  (IEA,ISO)
positive regulation of mitotic nuclear division  (IMP)
positive regulation of neuron projection development  (IMP)
positive regulation of p38MAPK cascade  (ISO)
positive regulation of peptidyl-serine phosphorylation  (IMP)
positive regulation of peptidyl-threonine phosphorylation  (IMP)
positive regulation of transcription by RNA polymerase II  (IEA,IMP,ISO)
protein autophosphorylation  (IDA)
reactive oxygen species metabolic process  (ISO)
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling  (ISO)
regulation of cellular response to oxidative stress  (ISO)
regulation of interleukin-6 production  (ISO)
regulation of plasma membrane bounded cell projection organization  (IEA)
response to acidic pH  (IEP)
response to organic cyclic compound  (IEP)
response to peptide hormone  (IEP)
response to xenobiotic stimulus  (IEP)
semaphorin-plexin signaling pathway  (IEA,ISO,ISS)
skeletal muscle tissue development  (ISO)
transmembrane receptor protein tyrosine kinase signaling pathway  (IBA,IEA)

Cellular Component


References - curated
# Reference Title Reference Citation
1. Involvement of receptor-type tyrosine kinase gene families in cardiac hypertrophy. Akiyama Y, etal., J Hypertens. 1999 Sep;17(9):1329-37.
2. Met, metastasis, motility and more. Birchmeier C, etal., Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25.
3. Nuclear and cytoplasmic expression of Met in oral squamous cell carcinoma and in an organotypic oral cancer model. Brusevold IJ, etal., Eur J Oral Sci. 2010 Aug;118(4):342-9. doi: 10.1111/j.1600-0722.2010.00747.x.
4. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and up-regulation of MMPs, HGF and VEGF. Bueno M, etal., J Gene Med. 2006 Nov;8(11):1291-9.
5. Ontogeny of hepatocyte growth factor and c-met/hgf receptor in rat pancreas. Calvo EL, etal., Biochem Biophys Res Commun. 1996 Dec 4;229(1):257-63.
6. Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Camp RL, etal., Cancer. 1999 Dec 1;86(11):2259-65.
7. A genetic variant that disrupts MET transcription is associated with autism. Campbell DB, etal., Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16834-9. Epub 2006 Oct 19.
8. Protective effects of amylin on reserpine-induced gastric damage in the rat. Cantarella G, etal., Pharmacol Res. 2007 Jul;56(1):27-34. Epub 2007 Mar 12.
9. Expression and functional role of hepatocyte growth factor receptor (C-MET) during postnatal rat testis development. Catizone A, etal., Endocrinology. 2001 May;142(5):1828-34.
10. Functional role of hepatocyte growth factor receptor during sperm maturation. Catizone A, etal., J Androl. 2002 Nov-Dec;23(6):911-8.
11. Hepatocyte growth factor up-regulates met expression in rat fetal hepatocytes in primary culture. de Juan C, etal., Biochem Biophys Res Commun. 1994 Nov 15;204(3):1364-70.
12. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Derksen PW, etal., Blood. 2002 Feb 15;99(4):1405-10.
13. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Di Renzo MF, etal., Cancer Res. 1995 Mar 1;55(5):1129-38.
14. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Di Renzo MF, etal., Clin Cancer Res. 1995 Feb;1(2):147-54.
15. Overexpression of the Met/HGF receptor in ovarian cancer. Di Renzo MF, etal., Int J Cancer. 1994 Sep 1;58(5):658-62.
16. Regulation of epithelial cell growth factor receptor protein and gene expression using a rat periodontitis model. Ekuni D, etal., J Periodontal Res. 2006 Aug;41(4):340-9.
17. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Farazi PA, etal., Cancer Res. 2006 Jul 1;66(13):6622-7.
18. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
19. The Met tyrosine kinase receptor in development and cancer. Gentile A, etal., Cancer Metastasis Rev. 2008 Mar;27(1):85-94.
20. c-Met confers protection against chronic liver tissue damage and fibrosis progression after bile duct ligation in mice. Giebeler A, etal., Gastroenterology. 2009 Jul;137(1):297-308, 308.e1-4. doi: 10.1053/j.gastro.2009.01.068. Epub 2009 Feb 5.
21. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
22. Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. Gonzalez A, etal., Circ Res. 2008 Mar 14;102(5):597-606. Epub 2008 Jan 17.
23. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. Hamanoue M, etal., J Neurosci Res. 1996 Mar 1;43(5):554-64.
24. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms. Hansel DE, etal., Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6152-8.
25. Gastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism. Hoffmann KM, etal., J Biol Chem. 2006 Dec 8;281(49):37705-19. Epub 2006 Oct 10.
26. Attenuation of glycerol-induced acute kidney injury by previous partial hepatectomy: role of hepatocyte growth factor/c-met axis in tubular protection. Homsi E, etal., Nephron Exp Nephrol. 2007;107(3):e95-106. Epub 2007 Oct 16.
27. Expression and phosphorylation of rat c-met/hepatocyte growth factor receptor during rat liver regeneration. Horimoto M, etal., J Hepatol 1995 Aug;23(2):174-83.
28. Expression of hepatocyte growth factor and c-met genes during hepatic differentiation and liver development in the rat. Hu Z, etal., Am J Pathol. 1993 Jun;142(6):1823-30.
29. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Humphrey PA, etal., Am J Pathol. 1995 Aug;147(2):386-96.
30. CD44v6 dependence of premetastatic niche preparation by exosomes. Jung T, etal., Neoplasia. 2009 Oct;11(10):1093-105.
31. c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Kiehne K, etal., Pancreas. 1997 Jul;15(1):35-40.
32. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Kim CH, etal., Head Neck. 2010 Dec;32(12):1655-64. doi: 10.1002/hed.21383.
33. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. Kitamura K, etal., J Neurosci Res. 2007 Aug 15;85(11):2332-42.
34. Hepatocyte specific deletion of c-Met leads to the development of severe non-alcoholic steatohepatitis in mice. Kroy DC, etal., J Hepatol. 2014 Oct;61(4):883-90. doi: 10.1016/j.jhep.2014.05.019. Epub 2014 May 15.
35. RAN GTPase is an effector of the invasive/metastatic phenotype induced by osteopontin. Kurisetty VV, etal., Oncogene. 2008 Dec 4;27(57):7139-49. Epub 2008 Sep 15.
36. Distinctive gene expression of receptor-type tyrosine kinase families during rat hepatocarcinogenesis. Kuroda H, etal., Int J Mol Med. 2002 May;9(5):473-80.
37. Ovarian-type stroma in hepatobiliary cystadenomas and pancreatic mucinous cystic neoplasms: an immunohistochemical study. Lam MM, etal., Am J Clin Pathol. 2008 Feb;129(2):211-8.
38. HGF protects rat mesangial cells from high-glucose-mediated oxidative stress. Li H, etal., Am J Nephrol. 2006;26(5):519-30. Epub 2006 Nov 22.
39. Hepatocyte growth factor and c-Met promote dendritic maturation during hippocampal neuron differentiation via the Akt pathway. Lim CS and Walikonis RS, Cell Signal. 2008 May;20(5):825-35. Epub 2007 Dec 27.
40. Overexpression of c-Met promotes invasion and metastasis of small oral tongue carcinoma. Lim YC, etal., Oral Oncol. 2012 Nov;48(11):1114-9. doi: 10.1016/j.oraloncology.2012.05.013. Epub 2012 Jun 14.
41. Further studies on aberrant gene expression associated with arsenic-induced malignant transformation in rat liver TRL1215 cells. Liu J, etal., Toxicol Appl Pharmacol. 2006 Nov 1;216(3):407-15. Epub 2006 Jun 20.
42. Primary structure of rat HGF receptor and induced expression in glomerular mesangial cells. Liu Y, etal., Am J Physiol 1996 Sep;271(3 Pt 2):F679-88.
43. In vivo and in vitro evidence for increased expression of HGF receptor in kidney of diabetic rat. Liu Y, etal., Am J Physiol. 1996 Dec;271(6 Pt 2):F1202-10.
44. Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. Liu Y, etal., J Pathol. 2007 May;212(1):12-9.
45. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment. Lonngren U, etal., Brain Res Bull. 2006 Dec 11;71(1-3):208-18. Epub 2006 Oct 2.
46. Adenosine administration accelerates progression of the cell cycle during rat liver regeneration induced by one-third hepatectomy. Mendieta-Condado E, etal., J Pharmacol Exp Ther. 2009 Oct;331(1):122-32. Epub 2009 Jul 28.
47. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
48. Co-Expression of Cox-2, C-Met and beta-catenin in Cells Forming Invasive front of Gallbladder Cancer. Moon WS, etal., Cancer Res Treat. 2005 Jun;37(3):171-6. Epub 2005 Jun 30.
49. Hepatocyte growth factor and c-met expression in Long-Evans Cinnamon rats with spontaneous hepatitis and hepatoma. Nakayama N, etal., Hepatology. 1996 Sep;24(3):596-602.
50. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. Nakazawa K, etal., J Pathol. 2005 Jul;206(3):356-65.
51. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Navab R, etal., Neoplasia. 2009 Dec;11(12):1292-300.
52. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
53. Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma. Noguchi O, etal., J Hepatol. 1996 Mar;24(3):286-92.
54. Gene expression of transforming growth factor-beta1 and hepatocyte growth factor during wound healing of injured rat vocal fold. Ohno T, etal., Laryngoscope. 2009 Apr;119(4):806-10.
55. Hepatocyte growth factor (HGF) promotes oligodendrocyte progenitor cell proliferation and inhibits its differentiation during postnatal development in the rat. Ohya W, etal., Brain Res. 2007 May 25;1147:51-65. Epub 2007 Feb 27.
56. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
57. Hepatocyte growth factor-induced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Orian-Rousseau V, etal., Mol Biol Cell. 2007 Jan;18(1):76-83. Epub 2006 Oct 25.
58. Expression of hepatocyte growth factor, keratinocyte growth factor and their receptors in experimental chronic pancreatitis. Otte JM, etal., Eur J Clin Invest. 2001 Oct;31(10):865-75.
59. New driver mutations in non-small-cell lung cancer. Pao W and Girard N, Lancet Oncol. 2011 Feb;12(2):175-80.
60. Cell cycle effects resulting from inhibition of hepatocyte growth factor and its receptor c-Met in regenerating rat livers by RNA interference. Paranjpe S, etal., Hepatology. 2007 Jun;45(6):1471-7.
61. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Park WS, etal., Cancer Res. 1999 Jan 15;59(2):307-10.
62. Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Peghini PL, etal., Clin Cancer Res. 2002 Jul;8(7):2273-85.
63. Modulation of hepatocyte growth factor and c-met in the rat mammary gland during pregnancy, lactation, and involution. Pepper MS, etal., Exp Cell Res 1995 Jul;219(1):204-10.
64. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Peschard P, etal., Mol Cell 2001 Nov;8(5):995-1004.
65. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
66. Overexpression of the gene for transmembrane 4 superfamily member 4 accelerates liver damage in rats treated with CCl4. Qiu J, etal., J Hepatol. 2007 Feb;46(2):266-75. Epub 2006 Oct 2.
67. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Ramos-Nino ME, etal., Cancer Res. 2003 Jul 1;63(13):3539-45.
68. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Rao UN, etal., Hum Pathol. 1997 Sep;28(9):1066-70.
69. GOA pipeline RGD automated data pipeline
70. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
71. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
72. Overexpression of hepatocyte growth factor and its receptor c-Met in nasal polyps. Rho HS, etal., Arch Otolaryngol Head Neck Surg. 2006 Sep;132(9):985-9.
73. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase. Rodrigues GA and Park M, Oncogene. 1994 Jul;9(7):2019-27.
74. Met expression and sarcoma tumorigenicity. Rong S, etal., Cancer Res. 1993 Nov 15;53(22):5355-60.
75. Potent antioxidant role of pirfenidone in experimental cirrhosis. Salazar-Montes A, etal., Eur J Pharmacol. 2008 Oct 24;595(1-3):69-77. Epub 2008 Jul 9.
76. Increased DNA binding activity of NF-kappaB, STAT-3, SMAD3 and AP-1 in acutely damaged liver. Salazar-Montes A, etal., World J Gastroenterol. 2006 Oct 7;12(37):5995-6001.
77. Somatic mutations of signaling genes in non-small-cell lung cancer. Sanders HR and Albitar M, Cancer Genet Cytogenet. 2010 Nov;203(1):7-15.
78. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Schmidt L, etal., Nat Genet. 1997 May;16(1):68-73.
79. Localization and functional role of hepatocyte growth factor (HGF) and its receptor c-met in the rat developing cerebral cortex. Sun W, etal., Brain Res Mol Brain Res 2002 Jun 30;103(1-2):36-48.
80. Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer. Sun W, etal., Onco Targets Ther. 2013 Sep 18;6:1315-23. doi: 10.2147/OTT.S50428. eCollection 2013.
81. In vivo detection of c-Met expression in a rat C6 glioma model. Towner RA, etal., J Cell Mol Med. 2008 Jan-Feb;12(1):174-86. Epub 2007 Jan 9.
82. In vivo detection of c-MET expression in a rat hepatocarcinogenesis model using molecularly targeted magnetic resonance imaging. Towner RA, etal., Mol Imaging. 2007 Jan-Feb;6(1):18-29.
83. Roles of hepatocyte growth factor and its receptor in gastric mucosa. A cell biological and molecular biological study. Tsuji S, etal., Dig Dis Sci. 1995 May;40(5):1132-9.
84. The receptor tyrosine kinase Met and its ligand hepatocyte growth factor are clustered at excitatory synapses and can enhance clustering of synaptic proteins. Tyndall SJ and Walikonis RS, Cell Cycle. 2006 Jul;5(14):1560-8. Epub 2006 Jul 17.
85. Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. Tyndall SJ and Walikonis RS, Synapse. 2007 Apr;61(4):199-204.
86. Immunolocalization of the hepatocyte growth factor (HGF) system in the rat ovary and the anti-apoptotic effect of HGF in rat ovarian granulosa cells in vitro. Uzumcu M, etal., Reproduction. 2006 Aug;132(2):291-9.
87. Independent amplification of two gene clusters on chromosome 4 in rat endometrial cancer: identification and molecular characterization. Walentinsson A, etal., Cancer Res 2001 Nov 15;61(22):8263-73.
88. A dual-color FISH gene map of the proximal region of rat Chromosome 4 and comparative analysis in human and mouse. Walentinsson A, etal., Mamm Genome 2001 Dec;12(12):900-8.
89. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Wong HH and Lemoine NR, Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):412-22. Epub 2009 Jun 9.
90. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Xu Z, etal., Exp Mol Med. 2018 Jan 5;50(1):e417. doi: 10.1038/emm.2017.158.
91. Effect of hepatocyte growth factor on methionine adenosyltransferase genes and growth is cell density-dependent in HepG2 cells. Yang H, etal., J Cell Physiol. 2007 Mar;210(3):766-73.
92. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Yeh CN, etal., Carcinogenesis. 2004 Apr;25(4):631-6. Epub 2003 Dec 4.
93. Targeting epidermal growth factor receptor: central signaling kinase in lung cancer. Yoshida T, etal., Biochem Pharmacol. 2010 Sep 1;80(5):613-23. Epub 2010 May 24.
94. Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Zeng G, etal., Exp Cell Res. 2006 Nov 1;312(18):3620-30. Epub 2006 Aug 10.
Additional References at PubMed
PMID:7565774   PMID:7651534   PMID:8166728   PMID:9271668   PMID:11061428   PMID:12397180   PMID:12538467   PMID:12543460   PMID:12897086   PMID:14500721   PMID:14517989   PMID:15218527  
PMID:15314156   PMID:15376315   PMID:16049329   PMID:16153003   PMID:16192631   PMID:16465395   PMID:16537482   PMID:16804967   PMID:16867273   PMID:18819921   PMID:19581412   PMID:19850054  
PMID:20539003   PMID:20624990   PMID:20655899   PMID:20814222   PMID:21072211   PMID:21134835   PMID:21490227   PMID:22245998   PMID:22521434   PMID:23024263   PMID:23348694   PMID:23618918  
PMID:23994610   PMID:25168379   PMID:25198505   PMID:25277788   PMID:25674220   PMID:26972715   PMID:28679425  


Comparative Map Data
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
mRatBN7.2445,790,456 - 45,898,139 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl445,790,791 - 45,897,876 (+)EnsemblmRatBN7.2 Ensembl
UTH_Rnor_SHR_Utx450,810,987 - 50,887,772 (+)NCBIRnor_SHRUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0446,731,994 - 46,808,783 (+)NCBIRnor_SHRSPUTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0445,147,966 - 45,224,887 (+)NCBIRnor_WKYUTH_Rnor_WKY_Bbb_1.0
Rnor_6.0444,747,467 - 44,854,628 (+)NCBIRnor6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl444,774,741 - 44,852,665 (+)EnsemblRnor6.0rn6Rnor6.0
Rnor_5.0445,354,290 - 45,461,638 (+)NCBIRnor5.0Rnor_5.0rn5Rnor5.0
RGSC_v3.4443,134,183 - 43,211,355 (+)NCBIRGSC3.4RGSC_v3.4rn4RGSC3.4
RGSC_v3.1443,280,529 - 43,358,391 (+)NCBI
Celera441,091,921 - 41,169,063 (+)NCBICelera
Cytogenetic Map4q22NCBI
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
GRCh387116,672,196 - 116,798,377 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl7116,672,196 - 116,798,377 (+)EnsemblGRCh38hg38GRCh38
GRCh377116,312,250 - 116,438,431 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 367116,099,695 - 116,225,676 (+)NCBINCBI36Build 36hg18NCBI36
Build 347115,906,409 - 116,032,390NCBI
Celera7111,119,882 - 111,245,969 (+)NCBICelera
Cytogenetic Map7q31.2NCBI
HuRef7110,678,023 - 110,804,134 (+)NCBIHuRef
CHM1_17116,246,063 - 116,372,044 (+)NCBICHM1_1
T2T-CHM13v2.07117,987,305 - 118,113,574 (+)NCBIT2T-CHM13v2.0
CRA_TCAGchr7v27115,707,906 - 115,833,890 (+)NCBI
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
GRCm39617,463,351 - 17,573,979 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl617,463,799 - 17,573,979 (+)EnsemblGRCm39 Ensembl
GRCm38617,463,349 - 17,573,980 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl617,463,800 - 17,573,980 (+)EnsemblGRCm38mm10GRCm38
MGSCv37617,413,957 - 17,523,980 (+)NCBIGRCm37MGSCv37mm9NCBIm37
MGSCv36617,441,241 - 17,521,823 (+)NCBIMGSCv36mm8
Celera617,538,386 - 17,649,457 (+)NCBICelera
Cytogenetic Map6A2NCBI
cM Map67.83NCBI
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
ChiLan1.0 EnsemblNW_00495543222,440,637 - 22,517,647 (+)EnsemblChiLan1.0
ChiLan1.0NW_00495543222,440,671 - 22,519,592 (+)NCBIChiLan1.0ChiLan1.0
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
NHGRI_mPanPan175,516,636 - 5,642,435 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v07108,646,278 - 108,772,238 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.17121,365,429 - 121,468,159 (+)NCBIpanpan1.1PanPan1.1panPan2
PanPan1.1 Ensembl7121,365,438 - 121,468,159 (+)Ensemblpanpan1.1panPan2
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
CanFam3.11455,599,047 - 55,711,626 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1455,598,337 - 55,724,027 (+)EnsemblCanFam3.1canFam3CanFam3.1
Dog10K_Boxer_Tasha1455,021,838 - 55,105,272 (+)NCBIDog10K_Boxer_Tasha
ROS_Cfam_1.01455,639,647 - 55,766,100 (+)NCBIROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1455,639,031 - 55,750,317 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11455,696,450 - 55,779,874 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01455,384,675 - 55,468,117 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01455,755,770 - 55,839,237 (+)NCBIUU_Cfam_GSD_1.0
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
HiC_Itri_2NW_02440511844,299,687 - 44,409,065 (+)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_0049365892,280,799 - 2,390,179 (-)EnsemblSpeTri2.0
SpeTri2.0NW_0049365892,280,803 - 2,390,179 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
Sscrofa11.1 Ensembl1829,426,048 - 29,541,512 (-)EnsemblSscrofa11.1susScr11Sscrofa11.1
Sscrofa11.11829,426,044 - 29,541,526 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.21831,646,160 - 31,693,836 (+)NCBISscrofa10.2Sscrofa10.2susScr3
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
ChlSab1.12185,370,574 - 85,486,405 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl2185,397,645 - 85,488,093 (+)EnsemblChlSab1.1ChlSab1.1 EnsemblchlSab2
Vero_WHO_p1.0NW_02366604218,245,769 - 18,362,778 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
HetGla_female_1.0 EnsemblNW_0046248272,587,966 - 2,723,995 (-)EnsemblHetGla_female_1.0HetGla_female_1.0 EnsemblhetGla2
HetGla 1.0NW_0046248272,589,157 - 2,724,065 (-)NCBIHetGla_female_1.0HetGla 1.0hetGla2


Variants in Met
342 total Variants
miRNA Target Status

Predicted Target Of
Summary Value
Count of predictions:107
Count of miRNA genes:79
Interacting mature miRNAs:85
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (
For more information about miRGate, see PMID:25858286 or access the full paper here.

QTLs in Region (mRatBN7.2)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
619616Bp79Blood pressure QTL 790.0292arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)4521460278882945Rat
2303168Bp330Blood pressure QTL 3304.250.017arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)45214602146446691Rat
2302371Stl22Serum triglyceride level QTL 225.15blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521829457114705Rat
1358203Stl19Serum triglyceride level QTL 192.80.002blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521829465958103Rat
631642Stl2Serum triglyceride level QTL 23.3blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)4521917856647776Rat
6478724Anxrr35Anxiety related response QTL 350.00449defecation behavior trait (VT:0010462)defecation measurement (CMO:0000997)41008408955084089Rat
6478766Anxrr47Anxiety related response QTL 470.09637locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)41008408955084089Rat
6478769Anxrr48Anxiety related response QTL 480.02514locomotor behavior trait (VT:0001392)amount of experiment time spent in a discrete space in an experimental apparatus (CMO:0000958)41008408955084089Rat
8694374Bw155Body weight QTL 1553.390.001body lean mass (VT:0010483)lean tissue morphological measurement (CMO:0002184)41008408955084089Rat
9590304Scort17Serum corticosterone level QTL 174.960.001blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)41008408955084089Rat
8552906Pigfal3Plasma insulin-like growth factor 1 level QTL 3blood insulin-like growth factor amount (VT:0010479)plasma insulin-like growth factor 1 level (CMO:0001299)41008408955084089Rat
631261Tcas3Tongue tumor susceptibility QTL 36.88tongue integrity trait (VT:0010553)number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950)41081417091360527Rat
2316958Gluco58Glucose level QTL 5810blood glucose amount (VT:0000188)blood glucose level (CMO:0000046)411320076180699135Rat
2303585Bw86Body weight QTL 864body mass (VT:0001259)body weight (CMO:0000012)41467806559678065Rat
2313401Anxrr27Anxiety related response QTL 27aggression-related behavior trait (VT:0015014)tameness/aggressiveness composite score (CMO:0002136)41793350862933508Rat
61412Pia2Pristane induced arthritis QTL 23.9joint integrity trait (VT:0010548)post-insult time to onset of experimental arthritis (CMO:0001450)42133334362278020Rat
6909122Insul22Insulin level QTL 224.63blood insulin amount (VT:0001560)plasma insulin level (CMO:0000342)42690728575585128Rat
6909128Pancm4Pancreatic morphology QTL 411.35pancreas mass (VT:0010144)pancreas wet weight (CMO:0000626)42690728575585128Rat
8655906Rf60Renal function QTL 603.8blood creatinine amount (VT:0005328)creatinine clearance (CMO:0000765)42949419581006281Rat
12798520Anxrr55Anxiety related response QTL 554.450.01locomotor behavior trait (VT:0001392)number of rearing movements with lid-pushing in an experimental apparatus (CMO:0002715)432583980114627242Rat
11530004Niddm71Non-insulin dependent diabetes mellitus QTL 710.001blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)43258419952754138Rat
8552782Vie1Viral induced encephalitis QTL 126.4brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)43443048482490359Rat
8552801Bw143Body weight QTL 1437.3body mass (VT:0001259)change in body weight to body weight ratio (CMO:0002216)43443048482490359Rat
8552809Vie5Viral induced encephalitis QTL 525.3brain integrity trait (VT:0010579)encephalitis incidence/prevalence measurement (CMO:0002361)43443048482490359Rat
8655961Kidm43Kidney mass QTL 4318kidney mass (VT:0002707)both kidneys wet weight (CMO:0000085)436303261103194984Rat
1358352Srcrt3Stress Responsive Cort QTL 32.29blood corticosterone amount (VT:0005345)plasma corticosterone level (CMO:0001173)438465774146803430Rat
61475Aia2Adjuvant induced arthritis QTL 25.8joint integrity trait (VT:0010548)joint inflammation composite score (CMO:0000919)43950527573892441Rat
1331807Rf31Renal function QTL 312.988urine potassium amount (VT:0010539)urine potassium level (CMO:0000128)43952426474726312Rat
1300139Hrtrt6Heart rate QTL 62.85heart pumping trait (VT:2000009)heart rate (CMO:0000002)439524264116179656Rat
61445Strs3Sensitivity to stroke QTL 33cerebrum integrity trait (VT:0010549)post-insult time to onset of cerebrovascular lesion (CMO:0002343)44043338885433388Rat
8694439Bw168Body weight QTL 1689.570.001retroperitoneal fat pad mass (VT:0010430)retroperitoneal fat pad weight to body weight ratio (CMO:0000635)44043341485433414Rat
6893678Bw108Body weight QTL 1082.60.006body mass (VT:0001259)body weight (CMO:0000012)44345797688457976Rat
1576305Emca6Estrogen-induced mammary cancer QTL 65.8mammary gland integrity trait (VT:0010552)mammary tumor number (CMO:0000343)444463720155883716Rat
1354612Foco1Food consumption QTL 18.87eating behavior trait (VT:0001431)food intake rate (CMO:0000427)444463908148090542Rat
1354660Salc1Saline consumption QTL 111.26drinking behavior trait (VT:0001422)saline drink intake rate (CMO:0001627)444463908148090542Rat
2312567Glom19Glomerulus QTL 191.90.006kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)445456990146803430Rat

Markers in Region
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2445,819,539 - 45,819,609 (+)MAPPERmRatBN7.2
Rnor_6.0444,776,028 - 44,776,097NCBIRnor6.0
Rnor_5.0445,383,042 - 45,383,111UniSTSRnor5.0
RGSC_v3.4443,134,878 - 43,134,947UniSTSRGSC3.4
Celera441,092,616 - 41,092,685UniSTS
Cytogenetic Map4q21UniSTS

Related Rat Strains
The following Strains have been annotated to Met

Genetic Models
This gene Met is modified in the following models/strains


RNA-SEQ Expression
High: > 1000 TPM value   Medium: Between 11 and 1000 TPM
Low: Between 0.5 and 10 TPM   Below Cutoff: < 0.5 TPM

alimentary part of gastrointestinal system circulatory system endocrine system exocrine system hemolymphoid system hepatobiliary system integumental system musculoskeletal system nervous system renal system reproductive system respiratory system appendage
Medium 2 38 28 6 28 8 8 11 35 28 11 8
Low 1 35 19 13 13 13 3 59 12
Below cutoff 7 4 1


RefSeq Acc Id: ENSRNOT00000086902   ⟹   ENSRNOP00000070486
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl445,790,791 - 45,897,876 (+)Ensembl
Rnor_6.0 Ensembl444,774,741 - 44,852,665 (+)Ensembl
RefSeq Acc Id: ENSRNOT00000115453   ⟹   ENSRNOP00000085968
Rat AssemblyChrPosition (strand)Source
mRatBN7.2 Ensembl445,790,791 - 45,897,876 (+)Ensembl
RefSeq Acc Id: NM_031517   ⟹   NP_113705
Rat AssemblyChrPosition (strand)Source
mRatBN7.2445,818,845 - 45,896,016 (+)NCBI
Rnor_6.0444,775,333 - 44,852,505 (+)NCBI
Rnor_5.0445,354,290 - 45,461,638 (+)NCBI
RGSC_v3.4443,134,183 - 43,211,355 (+)RGD
Celera441,091,921 - 41,169,063 (+)RGD
RefSeq Acc Id: XM_006236129   ⟹   XP_006236191
Rat AssemblyChrPosition (strand)Source
mRatBN7.2445,790,458 - 45,898,139 (+)NCBI
Rnor_6.0444,747,467 - 44,854,628 (+)NCBI
Rnor_5.0445,354,290 - 45,461,638 (+)NCBI
RefSeq Acc Id: XM_039107024   ⟹   XP_038962952
Rat AssemblyChrPosition (strand)Source
mRatBN7.2445,790,456 - 45,898,139 (+)NCBI
RefSeq Acc Id: NP_113705   ⟸   NM_031517
- Peptide Label: precursor
- UniProtKB: Q63964 (UniProtKB/Swiss-Prot),   Q63119 (UniProtKB/Swiss-Prot),   P97579 (UniProtKB/Swiss-Prot),   P97523 (UniProtKB/Swiss-Prot)
- Sequence:
RefSeq Acc Id: XP_006236191   ⟸   XM_006236129
- Peptide Label: isoform X1
- UniProtKB: Q63964 (UniProtKB/Swiss-Prot),   Q63119 (UniProtKB/Swiss-Prot),   P97579 (UniProtKB/Swiss-Prot),   P97523 (UniProtKB/Swiss-Prot),   Q2IBC7 (UniProtKB/TrEMBL),   A0A0G2JY19 (UniProtKB/TrEMBL),   A0A9K3Y8B9 (UniProtKB/TrEMBL)
- Sequence:
RefSeq Acc Id: ENSRNOP00000070486   ⟸   ENSRNOT00000086902
RefSeq Acc Id: XP_038962952   ⟸   XM_039107024
- Peptide Label: isoform X2
- UniProtKB: Q63964 (UniProtKB/Swiss-Prot),   Q63119 (UniProtKB/Swiss-Prot),   P97579 (UniProtKB/Swiss-Prot),   P97523 (UniProtKB/Swiss-Prot),   A0A8I6GEH2 (UniProtKB/TrEMBL)
RefSeq Acc Id: ENSRNOP00000085968   ⟸   ENSRNOT00000115453
Protein Domains
IPT/TIG   Protein kinase   Sema

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P97523-F1-model_v2 AlphaFold P97523 1-1382 view protein structure


eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3082 AgrOrtholog
BioCyc Gene G2FUF-45555 BioCyc
Ensembl Genes ENSRNOG00000052745 Ensembl, ENTREZGENE, UniProtKB/TrEMBL
Ensembl Protein ENSRNOP00000070486 ENTREZGENE
  ENSRNOP00000070486.2 UniProtKB/TrEMBL
  ENSRNOP00000085968.1 UniProtKB/TrEMBL
Ensembl Transcript ENSRNOT00000086902 ENTREZGENE
  ENSRNOT00000086902.2 UniProtKB/TrEMBL
  ENSRNOT00000115453.1 UniProtKB/TrEMBL
Gene3D-CATH UniProtKB/Swiss-Prot, UniProtKB/TrEMBL UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Transferase(Phosphotransferase) domain 1 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
InterPro Ig-like_fold UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ig_E-set UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  IPT_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Kinase-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Plexin UniProtKB/Swiss-Prot
  Plexin_repeat UniProtKB/TrEMBL
  Prot_kinase_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Protein_kinase_ATP_BS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PSI UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Semap_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Semap_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Ser-Thr/Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_AS UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_cat_dom UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Tyr_kinase_HGF/MSP_rcpt UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  WD40/YVTN_repeat-like_dom_sf UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
KEGG Report rno:24553 UniProtKB/Swiss-Prot
  PTHR22625 UniProtKB/Swiss-Prot
Pfam Pkinase_Tyr UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Sema UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TIG UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
PhenoGen Met PhenoGen
PIRSF TyrPK_HGF-R UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SEMA UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
SMART IPT UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  PSI UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  Sema UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  TyrKc UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
Superfamily-SCOP Plexin repeat UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF101912 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF56112 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
  SSF81296 UniProtKB/Swiss-Prot, UniProtKB/TrEMBL
UniProt Secondary A0A0G2JY19 UniProtKB/TrEMBL
  P97579 UniProtKB/Swiss-Prot
  Q63119 UniProtKB/Swiss-Prot
  Q63964 UniProtKB/Swiss-Prot

Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2014-07-10 Met  MET proto-oncogene, receptor tyrosine kinase  Met  met proto-oncogene  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2002-06-10 Met  met proto-oncogene      Symbol and Name status set to approved 70586 APPROVED

RGD Curation Notes
Note Type Note Reference
gene_cellular_localization C-Met codes for a 190 kDa transmembrane tyrosine kinase receptor 70321
gene_disease upregulated in hormone-dependent endometrial cancers 70557
gene_expression expressed in uterus 70557
gene_function receptor tyrosine kinase, receptor for hepatocyte growth factor  
gene_process has a role in cell signalling 70348
gene_process variant forms may be involved in oncogenesis 70557
gene_process may be involved in rat liver regeneration 729166
gene_product glycoprotein consisting of 1382 amino acids 70321